天士力2025年第三季度净利润同比增长16.56%

Core Insights - Tianjin Tasly Pharmaceutical announced a revenue of 2.022 billion yuan for Q3 2025, representing a year-on-year decline of 3.27% [1] - The net profit attributable to shareholders for Q3 2025 was 210 million yuan, showing a year-on-year increase of 16.56% [1] - For the first three quarters of 2025, the company reported a total revenue of 6.311 billion yuan, down 2.35% year-on-year [1] - The net profit attributable to shareholders for the first three quarters of 2025 reached 984 million yuan, reflecting a year-on-year growth of 16.88% [1]